Abemaciclib (LY2835219) in Ewing’s Sarcoma: CAMPFIRE

 

Trial name: CAMPFIRE: Abemaciclib (LY2835219) in Ewing's Sarcoma
Agents: Abemaciclib (LY2835219)
Phase II
Status Recruiting
Sponsor Eli Lilly and Company

 

This is a Phase II study that aims to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolamide) for Ewing's sarcoma that has come back or did not respond to treatment.

Further information can be found on clinicaltrials.gov.

 

WHO is the trial for?
  • Confirmed diagnosis of Ewing's sarcoma or Ewing's sarcoma-like tumor that has come back or did not respond to treatment
  • Previous treatment has stopped at least 7 days before, patients must have recovered from the acute effects
  • Overall health status of the patient has to be good 

WHAT is the key question that this trial is attempting to answer?

 The study measures the efficacy and safety of adding abemaciclib to chemotherapy (irinotecan and temozolamide).

WHY patients might want to participate?

 This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in sarcomas and potentially help other patients with this disease.

The trial might or might not have benefit in your individual case.

WHEN will the trial be open?

 The study is open for recruitment.

WHERE is the trial available?

 The trial is currently active in the US, Australia, France, Germany, Italy, Japan and Spain.

Please check for current information here.

Study contact:

  • Phone: 1-317-615-4559
  • Email: Clinicaltrials.gov@lilly.com

STUDY DESIGN: What does the study look like?

 The study consists of 2 arms: All participating patients will be randomly divided (by a computer) in two groups. One group will be assigned to Abemaciclib (LY2835219) plus Irinotecan and Temozolomide, the other group will receive only the combination of Irinotecan and Temozolomide.

Abemaciclib and Temozolomide are given orally (by mouth), Irinotecan is administered in the vein (intravenous IV).

HOW do I get more information?

 Patient organizations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organizations serving GIST and/or sarcoma patients. If there are no such organization in your country, please email us for more information: info@sarcoma-patients.org

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken